Home  |  Top News  |  Most Popular  |  Video  |  Multimedia  |  News Feeds  |  Feedback
  Medicine  |  Nature & Earth  |  Biology  |  Technology & Engineering  |  Space & Planetary  |  Psychology  |  Physics & Chemistry  |  Economics  |  Archaeology
Top > Medicine, Health Care > Blood Levels of Immune Protein… >
Blood Levels of Immune Protein Predict Risk in Hodgkin Disease

Published: December 10, 2012.
By Dana-Farber Cancer Institute
http://www.dfci.harvard.edu

Blood levels of an immunity-related protein, galectin-1, in patients with newly diagnosed Hodgkin lymphoma reflected the extent of their cancer and correlated with other predictors of outcome, scientists reported at the American Society of Hematology annual meeting.

In a study of 315 patients from a German database, researchers from Dana-Farber Cancer Institute found that serum galectin-1 levels "are significantly associated with tumor burden and additional adverse clinical characteristics in newly diagnosed Hodgkin lymphoma (HL) patients."

The measurements were made possible by a new laboratory test called a "sandwich ELISA" devised by the Dana-Farber team, led by Margaret Shipp, MD, director of the lymphoma program at Dana-Farber. Galectin-1 is a protein which, when overexpressed by Hodgkin lymphoma cells, allows them to evade the body's immune response that normally would detect the cancer and attack it with cell-killing lymphocytes. The Shipp group developed antibodies that recognize the galectin-1 protein and were used in developing the sandwich ELISA assay.

Since the protein is secreted into the bloodstream, the investigators hypothesized that measuring relative levels of galectin-1 in newly diagnosed, untreated Hodgkin patients could help to assess likely outcomes in those patients. Such predictions, in turn, could help physicians decide how aggressively to treat the lymphoma, Shipp explained. With further development, she added, the assay could become "an objective test that might help make decisions on which way to treat patients."

The Dana-Farber scientists collaborated with researchers of the German Hodgkin Study Group (GHSG) at the University Hospital of Cologne. Shipp said that the GHSG has "probably the largest, most comprehensive data on clinical trials of patient with well-defined Hodgkin lymphoma." The 315 patients whose blood levels of galactin-1 were tested in the study had been enrolled in three different clinical trials – one for early-stage disease, a second for early-stage disease with additional less-favorable risk factors, and the third for patients with bulky localized or advanced-stage disease.

Using the sandwich ELISA assay, the Dana-Farber investigators found that blood galectin-1 levels in Hodgkin lymphoma patients were significantly higher than in normal control patients. They also found that relative galectin-1 levels were correlated with the risk factors that had been used to assign the 315 patients to the three different clinical trials. Direct comparisons of the galectin-1 levels with patient outcomes are awaiting the completion of one of the clinical trials, the researchers noted.

Beyond the potential for a clinical test, galectin-1 holds promise as a therapeutic target, said Shipp, whose group has made a "neutralizing" antibody to block the protein. She said the antibody, which is produced in mice, would need to be "humanized," or genetically modified to be compatible with human patients, and then undergo rigorous testing for safety and efficacy. This is under discussion with potential industrial partners, said Shipp.




Translate this page: Chinese French German Italian Japanese Korean Portuguese Russian Spanish


 
All comments are reviewed before being posted. We cannot accept messages that refer a product, or web site.If you are looking for a response to a question please use our another feedback page.
Related »

Production 
10/13/11 
NIH-funded Researchers Correct Sickle Cell Disease in Adult Mice
By National Heart, Lung and Blood Institute
National Institutes of Health-funded scientists have corrected sickle cell disease in adult laboratory mice by activating production of a special blood component normally produced before, but not after, birth. …
Alcohol 
2/20/13 
Signaling Pathway Linked to Fetal Alcohol Risk
By Harvard Medical School
Fetal alcohol syndrome is the leading preventable cause of developmental disorders in developed countries. And fetal alcohol spectrum disorder (FASD), a range of alcohol-related birth defects that includes fetal …
Dlbcl 
11/1/10 
New Potential Drug Combination for Most Common Form of Non-Hodgkin's Lymphoma
By Journal of Clinical Investigation
Diffuse large B cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma. Although 60% of patients can be cured with a currently available combination therapy, this leaves …
Usc 
2/14/12 
★ 
USC Team Tracks Down Cause of Birth Defect
By University of Southern California
A USC research team has pinpointed the source of a genetic disorder that causes life-threatening birth defects, which may allow doctors to quickly diagnose and better treat the disease. …
Fxa 
10/24/11 
Bioengineered Protein Shows Preliminary Promise as New Therapy for Hemophilia
By Children's Hospital of Philadelphia
A genetically engineered clotting factor that controlled hemophilia in an animal study offers a novel potential treatment for human hemophilia and a broad range of other bleeding problems. …
More » 
 
© Newsline Group  |  About  |  Privacy Policy  |  Feedback  |  Mobile  |  Japanese Edition